Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa

Giuseppe Portale, Jeffrey H. Peters, Jeffrey A. Hagen, Steven R. DeMeester, Tasha A K Gandamihardja, Chadin Tharavej, Chih Cheng Hsieh, Tom R. DeMeester, Claude Deschamps, Kathrin Mayer, James Debord, Sherry Wren, John Hunter

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: The incidence of adenocarcinoma in the distal esophagus and at the gastroesophageal junction (GEJ) has been increasing in the last decades. It has been suggested that patients in whom Barrett mucosa can be identified in the surgical specimen have a better prognosis compared with those without. This has led to the belief that patients with and without Barrett mucosa may represent 2 distinct cancer types. Hypothesis: Distal esophageal-GEJ adenocarcinoma with and without Barrett mucosa share the same origin, but differ only in clinical presentation and outcome. Design and Setting: Retrospective cohort study in a university tertiary referral center. Patients and Methods: Between 1992 and 2002, 215 patients (173 men and 42 women; median age, 66 years; age range, 26-91 years) had esophagogastrectomy for adenocarcinoma of the distal esophagus-GEJ. Patients receiving neoadjuvant chemotherapy or radiation therapy were excluded. Main Outcome Measures: Clinical presentation, tumor characteristics, and survival were compared in patients with Barrett mucosa (n=140) and those without (n=75). Results: Patients with Barrett mucosa in the specimen had tumors that were diagnosed earlier; were smaller in size; earlier in stage, with fewer node metastases; and had a better 5-year survival. Conclusions: Observed differences in survival between patients with distal esophageal-GEJ adenocarcinoma with and without Barrett mucosa can be explained by earlier diagnosis. Patients without Barrett mucosa have their tumors detected later, when the disease is more advanced. This suggests the possibility that tumors without Barrett mucosa are not of a different origin, but rather are larger tumors that may have overgrown areas of Barrett mucosa.

Original languageEnglish (US)
Pages (from-to)570-575
Number of pages6
JournalArchives of Surgery
Volume140
Issue number6
DOIs
StatePublished - Jun 2005

Fingerprint

Esophagogastric Junction
Mucous Membrane
Adenocarcinoma
Survival
Neoplasms
Neoadjuvant Therapy
Tertiary Care Centers
Esophagus
Early Diagnosis
Cohort Studies
Radiotherapy
Retrospective Studies
Outcome Assessment (Health Care)
Neoplasm Metastasis
Drug Therapy

ASJC Scopus subject areas

  • Surgery

Cite this

Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa. / Portale, Giuseppe; Peters, Jeffrey H.; Hagen, Jeffrey A.; DeMeester, Steven R.; Gandamihardja, Tasha A K; Tharavej, Chadin; Hsieh, Chih Cheng; DeMeester, Tom R.; Deschamps, Claude; Mayer, Kathrin; Debord, James; Wren, Sherry; Hunter, John.

In: Archives of Surgery, Vol. 140, No. 6, 06.2005, p. 570-575.

Research output: Contribution to journalArticle

Portale, G, Peters, JH, Hagen, JA, DeMeester, SR, Gandamihardja, TAK, Tharavej, C, Hsieh, CC, DeMeester, TR, Deschamps, C, Mayer, K, Debord, J, Wren, S & Hunter, J 2005, 'Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa', Archives of Surgery, vol. 140, no. 6, pp. 570-575. https://doi.org/10.1001/archsurg.140.6.570
Portale, Giuseppe ; Peters, Jeffrey H. ; Hagen, Jeffrey A. ; DeMeester, Steven R. ; Gandamihardja, Tasha A K ; Tharavej, Chadin ; Hsieh, Chih Cheng ; DeMeester, Tom R. ; Deschamps, Claude ; Mayer, Kathrin ; Debord, James ; Wren, Sherry ; Hunter, John. / Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa. In: Archives of Surgery. 2005 ; Vol. 140, No. 6. pp. 570-575.
@article{76c41d744add443c870969096e8f0d53,
title = "Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa",
abstract = "Background: The incidence of adenocarcinoma in the distal esophagus and at the gastroesophageal junction (GEJ) has been increasing in the last decades. It has been suggested that patients in whom Barrett mucosa can be identified in the surgical specimen have a better prognosis compared with those without. This has led to the belief that patients with and without Barrett mucosa may represent 2 distinct cancer types. Hypothesis: Distal esophageal-GEJ adenocarcinoma with and without Barrett mucosa share the same origin, but differ only in clinical presentation and outcome. Design and Setting: Retrospective cohort study in a university tertiary referral center. Patients and Methods: Between 1992 and 2002, 215 patients (173 men and 42 women; median age, 66 years; age range, 26-91 years) had esophagogastrectomy for adenocarcinoma of the distal esophagus-GEJ. Patients receiving neoadjuvant chemotherapy or radiation therapy were excluded. Main Outcome Measures: Clinical presentation, tumor characteristics, and survival were compared in patients with Barrett mucosa (n=140) and those without (n=75). Results: Patients with Barrett mucosa in the specimen had tumors that were diagnosed earlier; were smaller in size; earlier in stage, with fewer node metastases; and had a better 5-year survival. Conclusions: Observed differences in survival between patients with distal esophageal-GEJ adenocarcinoma with and without Barrett mucosa can be explained by earlier diagnosis. Patients without Barrett mucosa have their tumors detected later, when the disease is more advanced. This suggests the possibility that tumors without Barrett mucosa are not of a different origin, but rather are larger tumors that may have overgrown areas of Barrett mucosa.",
author = "Giuseppe Portale and Peters, {Jeffrey H.} and Hagen, {Jeffrey A.} and DeMeester, {Steven R.} and Gandamihardja, {Tasha A K} and Chadin Tharavej and Hsieh, {Chih Cheng} and DeMeester, {Tom R.} and Claude Deschamps and Kathrin Mayer and James Debord and Sherry Wren and John Hunter",
year = "2005",
month = "6",
doi = "10.1001/archsurg.140.6.570",
language = "English (US)",
volume = "140",
pages = "570--575",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa

AU - Portale, Giuseppe

AU - Peters, Jeffrey H.

AU - Hagen, Jeffrey A.

AU - DeMeester, Steven R.

AU - Gandamihardja, Tasha A K

AU - Tharavej, Chadin

AU - Hsieh, Chih Cheng

AU - DeMeester, Tom R.

AU - Deschamps, Claude

AU - Mayer, Kathrin

AU - Debord, James

AU - Wren, Sherry

AU - Hunter, John

PY - 2005/6

Y1 - 2005/6

N2 - Background: The incidence of adenocarcinoma in the distal esophagus and at the gastroesophageal junction (GEJ) has been increasing in the last decades. It has been suggested that patients in whom Barrett mucosa can be identified in the surgical specimen have a better prognosis compared with those without. This has led to the belief that patients with and without Barrett mucosa may represent 2 distinct cancer types. Hypothesis: Distal esophageal-GEJ adenocarcinoma with and without Barrett mucosa share the same origin, but differ only in clinical presentation and outcome. Design and Setting: Retrospective cohort study in a university tertiary referral center. Patients and Methods: Between 1992 and 2002, 215 patients (173 men and 42 women; median age, 66 years; age range, 26-91 years) had esophagogastrectomy for adenocarcinoma of the distal esophagus-GEJ. Patients receiving neoadjuvant chemotherapy or radiation therapy were excluded. Main Outcome Measures: Clinical presentation, tumor characteristics, and survival were compared in patients with Barrett mucosa (n=140) and those without (n=75). Results: Patients with Barrett mucosa in the specimen had tumors that were diagnosed earlier; were smaller in size; earlier in stage, with fewer node metastases; and had a better 5-year survival. Conclusions: Observed differences in survival between patients with distal esophageal-GEJ adenocarcinoma with and without Barrett mucosa can be explained by earlier diagnosis. Patients without Barrett mucosa have their tumors detected later, when the disease is more advanced. This suggests the possibility that tumors without Barrett mucosa are not of a different origin, but rather are larger tumors that may have overgrown areas of Barrett mucosa.

AB - Background: The incidence of adenocarcinoma in the distal esophagus and at the gastroesophageal junction (GEJ) has been increasing in the last decades. It has been suggested that patients in whom Barrett mucosa can be identified in the surgical specimen have a better prognosis compared with those without. This has led to the belief that patients with and without Barrett mucosa may represent 2 distinct cancer types. Hypothesis: Distal esophageal-GEJ adenocarcinoma with and without Barrett mucosa share the same origin, but differ only in clinical presentation and outcome. Design and Setting: Retrospective cohort study in a university tertiary referral center. Patients and Methods: Between 1992 and 2002, 215 patients (173 men and 42 women; median age, 66 years; age range, 26-91 years) had esophagogastrectomy for adenocarcinoma of the distal esophagus-GEJ. Patients receiving neoadjuvant chemotherapy or radiation therapy were excluded. Main Outcome Measures: Clinical presentation, tumor characteristics, and survival were compared in patients with Barrett mucosa (n=140) and those without (n=75). Results: Patients with Barrett mucosa in the specimen had tumors that were diagnosed earlier; were smaller in size; earlier in stage, with fewer node metastases; and had a better 5-year survival. Conclusions: Observed differences in survival between patients with distal esophageal-GEJ adenocarcinoma with and without Barrett mucosa can be explained by earlier diagnosis. Patients without Barrett mucosa have their tumors detected later, when the disease is more advanced. This suggests the possibility that tumors without Barrett mucosa are not of a different origin, but rather are larger tumors that may have overgrown areas of Barrett mucosa.

UR - http://www.scopus.com/inward/record.url?scp=21244456551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244456551&partnerID=8YFLogxK

U2 - 10.1001/archsurg.140.6.570

DO - 10.1001/archsurg.140.6.570

M3 - Article

C2 - 15967904

AN - SCOPUS:21244456551

VL - 140

SP - 570

EP - 575

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 6

ER -